Thank you, Mr. Chair, and thank you, ladies and gentlemen, for your presentations today.
I'm more confused than ever. I sit here listening to pharmaceutical companies saying they're not concerned about the TPP, and yet I hear from a lot of other people who say they should be. I guess one of you is being tricked.
I want to start with Mr. Labonté. If I remember correctly, in your opening remarks, you forecasted an increase of $2 billion to $3 billion in pharmaceutical costs by 2030. Did I get that right?